Impact of gestrinone on the course of asymptomatic endometriosis. (1/4)
A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p = 0.002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p = 0.057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p = 0.004), confirming that gestrinone is an effective treatment of endometriosis. Endometriosis deteriorates in at least 23% of patients; as it is impossible to predict in whom this will happen, treatment appears to be warranted in all cases. (+info)Successful treatment of asymptomatic endometriosis: does it benefit infertile women? (2/4)
The relation between asymptomatic endometriosis and infertility was investigated in a randomised double blind placebo controlled trial of the impact of treating the endometriosis with gestrinone. The 12 month cumulative conception rate in those patients treated with gestrinone was 25% (5/20) and in those given placebo 24% (4/17). These same patients were divided into those in whom no visible endometriosis was present at the second laparoscopy and those in whom residual disease was present and the 12 month cumulative conception rates were 25% (4/16) and 30% (6/20) respectively. None of these rates differed significantly, and they compared with a rate of 23% (6/26) in a control group of patients with unexplained infertility. Those patients in whom the disease was eliminated did not return to normal fertility, though all other causes of infertility were excluded. This study failed to show any impact of treatment or the absence or presence of asymptomatic endometriosis on future fertility compared with patients with unexplained infertility. The findings therefore question any causal role of the disease in infertility. (+info)Clinical significance of compound quinestrol-caused glucose intolerance.(3/4)
(+info)Investigation of the influence of progesterone on mouse embryo transport by using antiprogestational steroids. (4/4)
The rate of embryo transport through the mouse oviduct was unaltered by ovariectomy after ovulation, essentially unaltered by administration of progesterone after ovulation but increased by preovulatory administration of progesterone. The antiprogestational steroid RMI 12,936 caused an arrest of embryo movement when given on Day 1, 2 or 3 of pregnancy and similar, though less marked, delay was caused by R2323, another progesterone antagonist. The effects of RMI 12,936 given on Day 1 were reversed by progesterone administration after a latent period of 24-48 h. These results indicate that the egg transport process in the mouse in triggered by progesterone and requires continued progesterone activity for its maintenance. (+info)Norpregnatrienes are steroidal compounds that contain a norpregnane nucleus, which is characterized by a pregnane skeleton with the elimination of one methyl group at C-10 position, and three carbon-carbon double bonds in the rings.
Norpregnatrienes are a subclass of steroids that contain a nor-group, which is a reduced ring structure where one methyl group has been removed, and three double bonds in the steroid nucleus. They do not have any clinical or medical significance in human physiology, but they can be found as metabolic intermediates in the biosynthesis of certain steroid hormones in some animals and microorganisms. Norpregnatrienes are primarily studied in the context of steroid research and biochemistry.